News

MaRS Innovation announces new strategic partnership with Pfizer

TORONTO, April 22, 2013 — MaRS Innovation, a Centre of Excellence for Commercialization and Research, today announced the formation of a strategic partnership with Pfizer Inc. to advance early-stage technologies related to human health in therapeutics and diagnostics.

Through this collaboration, MaRS Innovation and Pfizer will jointly identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals.

“There’s growing consensus that transferring technologies from the university lab bench and into the market requires unique public-private partnerships,” said Dr. Raphael Hofstein, president and CEO of MaRS Innovation. “Partnering with MaRS Innovation gives Pfizer access to Toronto’s robust innovation pipeline and a close look at emerging IP from Canada. It signals both the strength and attractiveness of our commercialization model and Toronto-based research technologies to global industry players.”

“Our government is committed to making Ontario the best place to translate great ideas into innovative products that will gain demand around the world,” said the Honourable Reza Moridi, Ontario Minister of Research and Innovation. “Today’s announcement from MaRS Innovation is an exciting collaboration with Pfizer that will both advance healthcare technologies for Ontarians and help to strengthen our economy.”

Merck invests in pan-Canadian life sciences research innovation sector

A $4-million public-private partnership will promote research innovation involving three academic commercialization centres in Canada

CHICAGO, Illinois – April 22, 2013 – Merck Canada will be announcing today at the BIO International Convention that it is reinforcing its commitment to the Canadian life sciences research innovation sector.

Merck will provide $4 million in funding to the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) for future corridor projects developed in collaboration with two other Canadian Centres of Excellence for Commercialization and Research (CECRs) based in Ontario and in British Columbia.

This partnership announcement was covered by PEHub.

IRICoR will work in conjunction with MaRS Innovation and the Centre for Drug Research and Development (CDRD) to identify, develop and commercialize technologies in healthcare. All three CECR institutions – identified as CECR in 2008 by the federal government – share a common objective: facilitating and accelerating the commercialization of research breakthroughs that will improve the quality of life of Canadians and others around the world.

Minuum’s crowdfunding campaign raises 873 per cent of initial goal

Over 9,600 people funded Toronto start-up’s one-dimensional mobile keyboard

Final tally for Minuum's Indiegogo campaign — The final tally for Minuum’s Indiegogo campaign: $87,369 in one month from 9,648 supporters.

TORONTO, Canada (April 18, 2013) — The Indiegogo campaign for Minuum, “the little keyboard for big fingers,” created by Whirlscape Inc., has closed after raising $87,369 in one month.

Minuum is a one-dimensional, tiny keyboard that frees up mobile screen space while allowing fast, accurate typing. Its specialized, patent-protected auto-correction algorithm allows highly imprecise typing, configuring the difference between what you type and what you mean in real time and getting it right even if you miss every single letter.

Read about the Minuum launch and reaching its $60,000 stretch milestone in previous posts. The posts include links to Minuum’s international media coverage. Most recently, their technology and Indiegogo success were featured in The Verge, the Financial Post, Mobile Syrup (includes an excellent Youtube interview with founder Will Walmsley, embedded below) and Tech2.

The campaign’s initial goal — $10,000 to fund the launch of an Android keyboard app — was reached within 14 hours. Since its launch on March 18, the campaign video has been viewed over 1.1 million times.

Did you know Minuum’s campaign is in Indiegogo’s top 10 of all time for projects with the largest number of supporters?

Stem Cell Therapeutics licenses UHN’s Clinical Cancer Stem Cell Program

Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp. (TSX-V: SSS), a biopharmaceutical company developing cancer stem cell-related technologies, has signed a definitive license agreement with University Health Network (UHN), Toronto, Canada.

The agreement, developed in collaboration with MaRS Innovation, provides Stem Cell Therapeutics (SCT) with exclusive worldwide rights to an innovative clinical cancer stem cell program.

This announcement builds upon the existing stem cell program agreement between MI, Stem Cell Therapeutics and UHN, which was announced in November 2012.

The initial consideration of $1.6 million for the UHN License is to be satisfied by the issuance of 5,028,571 SCT common shares and 1,600,000 SCT common share purchase warrants to UHN and MaRS Innovation, each warrant allowing its holder to acquire one additional common share at an exercise price of $0.40 until March 15, 2018.

Is screening air travellers effective in containing a pandemic?

April 10, 2013
Susanne Staer
BlueDot

Toronto Star covers Khan’s new WHO paper on H1N1 outbreak

Dr. Kamran Khan, founder of BioDiaspora and an infectious disease physician and scientist at St. Michael’s Hospital, is among the experts studying the emergence of the H7N9 bird flu outbreak in China and the new coronavirus in the Middle East and Europe.

Global News National also covered this story on April 11, 2013. Watch Beatrice Politi and Carmen Chai‘s report, “Canadian scientists pioneer new formula in airport disease screening,” on the Global website.

The Toronto Star featured Khan’s research and BioDiaspora following the publication of his new paper in the Bulletin of the World Health Organization which assessed the impact of airport screenings in containing the 2009 H1N1 outbreak in Mexico.

Khan’s findings were covered in “Airport disease screening rarely worthwhile, Toronto study says,” by Helen Branswell.

BioDiaspora Founder: Travellers unlikely to bring H7N9 bird flu to Canada

April 9, 2013
Susanne Staer
BlueDot

Jennifer Yang interviewed Khan in today’s Toronto Star about the likelihood of the disease being easily transmitted from human to human or arriving in Canada, as SARS did in 2003.

Here’s an excerpt:

“This isn’t necessarily an event that poses a significant risk to Canada, at least based on all the current knowledge,” said Dr. Kamran Khan, an infectious disease specialist at St. Michael’s Hospital and founder of BioDiaspora, a program that predicts the potential spread of outbreaks. “Even if a case were to find its way into Canada, the likelihood of it spreading locally is quite low.”

BioDiaspora collects data on everything from air travel and weather to global distribution of disease-carrying insects and uses this data to forecast the potential spread of new diseases.

It has already performed a risk analysis of H7N9 for the U.S. Centers for Disease Control and Prevention, which contacted Khan last Tuesday for help.

Dr. Kamran Khan, founder of BioDiaspora, among experts studying emergence of coronavirus

April 5, 2013
Susanne Staer
BlueDot

Health risk to Canadians is currently low

Dr. Kamran Khan, founder of BioDiaspora and an infectious disease physician and scientist at St. Michael’s Hospital, is among the experts studying the emergence of the coronavirus.

Carolyn Brown interviewed Khan for a recent CMAJ article on the viral outbreak, “New coronavirus with ‘pandemic potential’ sparks global surveillance efforts.”

National Post: How does Canada solve its commercialization conundrum?

Government has key role to play as early-stage technology adopter says CEO Raphael Hofstein

Dr. Raphael Hofstein, president and CEO of MaRS Innovation, was quoted in Mary Theresa Bitti‘s National Post article, “Commercialization Conundrum: Canada must turn ideas into social and economic value,” published April 3, 2013.

The article examines Canada’s worsening track record in realizing commercialization gains based on the country’s significant per-capita investment in R&D.

Here’s an excerpt:

While Canada punches above its weight class when it comes to generating ideas — witness countless academic journals showcasing Canadian research — as a country, we are experiencing a failure to launch when it comes to commercializing those ideas and getting them to market. The Jenkins panel report on innovation spelled it out quite clearly, “Too many of the big ideas [Canada] generates wind up generating wealth for others.” Canada ranks 14th out of 17 peer countries when it comes to innovation, even though on a per-capita basis, our $7-billion federal annual investment into research and development (R&D) is far more generous than other OECD nations. The result: Our global competitiveness continues to slide. According to the World Economic Forum, Canada has dropped to 14th place in 2012 from 10th in 2010.

What does MaRS Innovation’s funding extension mean for Toronto’s academic entrepreneurs?

Every six weeks, MaRS Innovation’s marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI’s activities or one of our start-up companies. You can read the original post on the MaRS blog.

Created in 2008, MaRS Innovation (MI) bridges the chasm between the early-stage technologies emerging from its 16 member institutions and successful startup companies and licensable technologies.

By offering early-stage funding in tandem with hands-on management, business development, mentorship and intellectual property protection strategy, MI acts as a commercialization agent for its members and researchers.

Earlier this year, the Networks of Centres of Excellence of Canada awarded MI $14.95 million to continue its mandate as a Centre of Excellence for Commercialization and Research (CECR), matched by $25 million from membership fees and private sector investments.

So what does that success mean for MI’s ability to serve the needs of academic entrepreneurs based in Toronto?

Minuum closes on $60,000 crowdfunded stretch goal to build wearable development kit

Minuum's one-line QWERTY keyboard on a touch device — Minuum’s one-line QWERTY keyboard on a touch device leaves more screen space for content.

Whirlscape Inc.‘s Minuum keyboard has enjoyed the kind of launch that start-up founders dream about yet few achieve.

UPDATE: Whirlscape’s Minuum Project has now cleared its $60,000 fundraising target. Mobile Syrup wrote a follow-up article on the campaign with details about the Wearable Development Kit. Their technology also got a second spot on CTV News‘s Tech Tuesday report and was featured on Global TV’s The Morning Show.

The little keyboard for big fingers, which launched an Indiegogo campaign a week ago today to support the launch of its Android keyboard app and a wearable development kit, is currently less than $4,000 from its crowd-funded stretch goal of $60,000.

The company was featured on CTV News on Mar. 24, 2013. The CTV video story and photos of CEO Will Walmsley and CTO Xavier Snelgrove are available on CTV’s website.